Introduction
============

Kidney transplantation has long been considered the optimal treatment therapy for persons with ESRD. Dialysis, although itself a life-extending therapy, exacts its own toll on persons with renal failure. Hemodialysis therapy requires the patient to be attached to a machine three times a week for 3-4 hours each session ([@b16-hcfr-17-2-89]). Adverse reactions such as cramps and hypotension can be a problem, as well as shunt-access failure requiring additional vascular-access procedures. Although recombinant human erythropoeitin has improved hematocrit levels among dialysis patients, anemia remains a serious comorbidity for these patients. Continuous ambulatory peritoneal dialysis frees the patient from the machine but requires an exchange of peritoneal dialysate fluid four times daily. Continuous cycling peritoneal dialysis reduces the number of daytime exchanges but requires a machine assist at night. In addition, peritonitis is a continual problem for both forms of peritoneal dialysis ([@b14-hcfr-17-2-89]).

Transplantation frees patients from the various limitations imposed by dialysis regimens. Patients must take immunosuppressive drugs as long as the grafted kidney continues to function. Although these drugs can have adverse side effects, not the least of which is an impaired immune system, it is generally agreed that the quality of life for patients with a functioning kidney graft is superior to that on dialysis ([@b4-hcfr-17-2-89]). In addition, kidney transplantation represents a net savings in costs, both to the government and in total health care expenditures ([@b2-hcfr-17-2-89]). In recent years, improved graft survival rates have further enhanced the desirability of transplantation ([@b16-hcfr-17-2-89]).

There are insufficient cadaver kidney organs to transplant all persons who could benefit ([@b5-hcfr-17-2-89]). Consequently, the equitable allocation of this scarce resource has been of great concern to ESRD patients, providers, and policymakers ([@b11-hcfr-17-2-89]). Part of the rationale behind the creation of the Organ Procurement and Transplantation Network (OPTN) in 1984 was to ensure that organs were allocated in the fairest manner possible.[^1^](#fn1-hcfr-17-2-89){ref-type="fn"} Despite this concern, inequities remain. Numerous authors have documented the fact that black persons with ESRD are much less likely to get a transplant or will wait longer to get a transplant than do white persons ([@b12-hcfr-17-2-89]; [@b3-hcfr-17-2-89]; [@b9-hcfr-17-2-89]; [@b10-hcfr-17-2-89]; [@b15-hcfr-17-2-89]; [@b7-hcfr-17-2-89]).

One of the differences among the studies cited is the manner in which access to transplantation was measured. For example, because living donor transplant rates are far lower among black persons than among white persons, the inclusion of living donor transplants in the calculation of rates greatly affects the black/white ratio. Kjellstrand merely compared the racial distribution of dialysis patients with the racial distribution of all transplant (cadaver and living donor) patients. Eggers calculated the percent of ESRD patients with a functioning kidney (cadaver or living donor) graft. The others used multivariate time-to-event models. Held et al. calculated access from the time of renal failure until (cadaver) transplant Gaylin et al. used the same model but added a number of comorbidity factors and included living donor transplants. Sanfillippo et al. and Kallich, Wyant, and Krushat used the national OPTN wait list data to measure access (to cadaver transplant) in terms of median waiting time from the time a person enters the wait list until transplant. Despite these differences in methods, all researchers find similar results with respect to race---black beneficiaries have less access to kidney transplantation than do white ESRD beneficiaries.

One aspect of access to kidney transplantation that has not been measured to date is access to the national OPTN wait list. This is because the national registry of ESRD patients (the HCFA ESRD Program Management and Medical Information System \[PMMIS\]) has not been linked with the OPTN wait list. HCFA records do not contain information on when someone gets on the wait list; OPTN data do not contain information on ESRD persons who do not enroll onto the wait list. This article reports on the results of a matching of HCFA and OPTN data files and the development of a new measure of transplantation access. The analyses shed new light on the process of kidney transplantation and the places in the process where racial discrepancies are greatest.

Methods and Data
================

Two data sets were matched for this analysis: the OPTN wait list data sets and the HCFA ESRD PMMIS. A description of these two data sets follows:

OPTN Wait List Data
-------------------

The OPTN wait list data consist of two files, the current active wait list file and the removals file, which contains information on persons no longer on the active list. Both files were updated through May of 1994. The wait list file contained 26,025 records and the removals file had 76,417 records. Persons can be listed on both files and/or multiply listed on either file due to a number of reasons. For example, a person can be listed at more than one transplant center, in which case he/she would appear more than once on the active file. Similarly, a person who has received two transplants would appear twice on the removals file. Also, persons awaiting a transplant following a failed first transplant would be on both the active wait list and the removals list. Combining the two files and removing duplicate records resulted in an unduplicated file of 85,659 people.

HCFA ESRD PMMIS
---------------

The ESRD PMMIS is a longitudinal file of ESRD patients entitled to Medicare benefits that is maintained by HCFA\'s Bureau of Data Management and Strategy. In addition to the basic enrollment data available for all Medicare beneficiaries, such as gender, race,[^2^](#fn2-hcfr-17-2-89){ref-type="fn"} date of birth, date of death, and entitlement dates, the PMMIS contains information unique to ESRD beneficiaries. The medical evidence form (HCFA-2728) is used to determine date and cause of renal failure. All kidney transplants are reported on the Form HCFA-2745.[^3^](#fn3-hcfr-17-2-89){ref-type="fn"} The ESRD PMMIS file used in this study was updated through April 1994. This update of the ESRD PMMIS contained 582,330 people, the complete count of Medicare ESRD patients ever entitled since 1978.

Match of HCFA and OPTN Records
------------------------------

The OPTN and HCFA data sets were matched on the basis of Medicare Health Insurance Claim (HIC) number. According to the 1992 annual ESRD facility survey, Medicare beneficiaries account for about 90-92 percent of all kidney transplants ([@b8-hcfr-17-2-89]). Therefore, it would seem that the match rate would not exceed 90 or 92 percent. Of the 85,659 persons included in the OPTN files, 74,135 (86.5 percent) matched the ESRD PMMIS on HIC. Given that reporting lags are greater in the ESRD PMMIS than in the OPTN files, there are undoubtedly more people in the OPTN files who will match the ESRD PMMIS once it gets fully updated.

[Table 1](#t1-hcfr-17-2-89){ref-type="table"} shows the match rate by year of OPTN entry. The match rate for 1992 and earlier years ranges from 88-90 percent (compared with the maximum expected match of 90 to 92 percent) but drops to 81.3 percent for 1993. Generally, the ESRD PMMIS is not considered completely updated until at least 15 months after the end of a year (i.e., April 1995 update for calendar year 1993). Therefore, it appears that the OPTN/ESRD PMMIS match is at least 95 percent successful---sufficient for analyses of transplantation access.

Given the successful match of OPTN and HCFA data, an analytical file was created to develop measures of transplant access. The Medicare ESRD incident cohort from 1988-92 was used in the analysis. Incident cases who received transplants prior to this time may be missed due to the relatively recent start-up of the OPTN data system. Incident cases after this time may be missing due to lags in updating the HCFA PMMIS.

For the analyses based on the ESRD incident population, the study was limited to persons under 55 years of age (*n* = 79,527). Although transplantation is increasingly being made available to older persons with ESRD, it still is predominantly a therapy for younger persons. People 55 years of age or over account for two-thirds of incident ESRD cases but only 17 percent of all transplants. It was felt that the inclusion of the older ESRD population would skew the access measures downward due to the inclusion of a large number of ESRD patients who, at this point in the development of renal therapy, could not be serious candidates for transplantation.[^4^](#fn4-hcfr-17-2-89){ref-type="fn"} For the analyses in which the denominator was wait list enrollment, no age selection was done. It was felt that enrollment in the OPTN was prima facie evidence that a person was an eligible candidate.

Measures
========

Three measures of access to transplantation were derived for this analysis. In all three cases, a time-to-event model was used with measure-specific censoring.

Access to Transplantation
-------------------------

This is the most direct and, ultimately, the most relevant measure of access. This is roughly defined as the percent of ESRD patients who get a transplant. This measure can be calculated directly from ESRD PMMIS data and does not require a link with OPTN data. The start date is the date of renal failure, taken from the medical evidence form. The outcome of interest is a transplant, either cadaveric or living donor. Patients are censored either at death or the end of the observation period (April 30, 1994).

Access to the OPTN Transplant Waiting List
------------------------------------------

This is, for most persons, the intermediate step between renal failure and a cadaveric transplant. In order to compete for the limited number of cadaver kidneys, one has to be wait listed. In essence, it measures one\'s eligibility to get a cadaver transplant. This requires linkage of HCFA and OPTN data. A major weakness of this measure is that it does not deal with the issue of living donor transplants. In 1993, 26 percent of kidney transplants were living donor transplants, up from 20 percent in 1985. The start date is the date of renal failure, taken from the medical evidence form. The end point is the earliest date of enrollment on the OPTN wait list. Censoring events include death, end of observation period, and any transplant (usually living donor) that may have occurred without first wait listing.

Access to Transplantation After Being Wait Listed
-------------------------------------------------

This is the logical followup to the previous measure. After having achieved the intermediate step of being wait listed, it measures what percent of patients actually get a transplant, or how long it takes to get a transplant. This measure can be calculated directly from OPTN data and has been the subject of a number of studies of transplant access. The start date is the date of wait listing. The end point is a cadaver transplant Living donor transplants were used as censoring events for this measure because a living related donor transplant is not the outcome for which the wait list is designed. Other censoring events included death, end of observation period, and any disenrollment from the OPTN wait list.[^5^](#fn5-hcfr-17-2-89){ref-type="fn"}

Descriptive tables of the time-to-event models showing bivariate effects of race, age, sex, and primary cause of renal failure are presented. In addition, proportional hazards models were constructed for each measure. As noted in the results section, the data do not support the proportionality assumption for this hazards model. However, the proportional hazards model does give a reasonable average estimate of covariate effects over the entire time span included in the analysis.

Results
=======

[Table 2](#t2-hcfr-17-2-89){ref-type="table"} shows a demographic breakdown by race of the Medicare ESRD population included in the study. There were a total of 79,527 persons under 55 years of age who initiated renal replacement therapy during these years. Black persons were most likely to have their renal failure attributed to hypertension (34.1 percent), whereas Native Americans had the highest percentage attributed to diabetes (59.1 percent). Males comprised the majority of persons in all racial groups, ranging from 52.8 percent for Asian-Americans to 59.8 percent for black persons. With the exception of Native Americans, there was little difference in the age distribution. Over one-half of Native Americans were over 45 years of age and their mean age was 3-4 years greater than other racial groups. Overall, the annual rate of renal failure (incidence) was 81 per million population. Incidence was comparable between Asian-American and white beneficiaries. However, compared with white persons, Native Americans were twice as likely, and black persons almost four times as likely, to suffer renal failure.

[Table 3](#t3-hcfr-17-2-89){ref-type="table"} shows the rate of transplantation for the 1988-92 Medicare ESRD incident cohort under 55 years of age. About one in six (16.1 percent) had received a transplant within 1 year of renal failure. After 3 years, over one-third of patients (36.7 percent) had received a transplant; after 5 years, almost one-half (46.1 percent) of patients had received at least one transplant.[^6^](#fn6-hcfr-17-2-89){ref-type="fn"} Access to transplantation is inversely related to age, decreasing from 45.7 percent (at 1 year following renal failure) for persons under 15 years of age to 8.1 percent for persons 45-54 years of age. Males are more likely to be transplanted than are females. At 5 years post renal failure, the transplantation rate among males is 47.8 percent, compared with 44.2 percent among females. At 1 year following renal failure, white persons are almost four times more likely to have received a transplant than black persons (22.7 percent and 6.0 percent, respectively). Asian-Americans (15.5 percent) and Native Americans (12.1 percent) also have transplantation rates more than double the rate of black persons. At 5 years post renal failure, fewer than one-third of black persons (30.3 percent) have received a transplant, while well over one-half (56.7 percent) of white persons have received a transplant. Asian-Americans have the highest transplantation rate at 5 years (58.2 percent). Transplantation rates also vary across causes of renal failure. The highest rates (at 1 year) are found for cystic kidney disease (25.5 percent), obstructive nephropathy (24.9 percent), and glomerulonephritis (23.2 percent). The lowest rates are found for hypertension (8.5 percent) and diabetes (13.3 percent). Part of the diagnostic difference is probably due to age; both hypertensive and diabetic ESRD patients tend to be older than the other diagnostic groups.

Rates of wait listing following renal failure among Medicare ESRD beneficiaries are shown in [Table 4](#t4-hcfr-17-2-89){ref-type="table"}. Compared with transplantation, which occurs more evenly throughout the 5-year period, wait listing is much more likely to occur within the first year after renal failure. About one-fourth (25.8 percent) of ESRD beneficiaries are wait listed within 1 year of renal failure. Almost one-half of patients have been wait listed at the end of 5 years. That is, about one-half of all the persons who get wait listed within 5 years of renal failure do so within the first year. The effect of living donor transplantation is also shown in the wait list rates. Although children (under 15 years of age) have the highest rate of transplantation ([Table 3](#t3-hcfr-17-2-89){ref-type="table"}), they are less likely to be wait listed than any other age group except those 45 to 54 years of age. Therefore, this measure is somewhat misleading as a measure of access to transplantation for pediatric ESRD patients.

As with transplantation rates in general ([Table 3](#t3-hcfr-17-2-89){ref-type="table"}), black ESRD beneficiaries are the least likely to get wait listed of all racial groups, with only 17.8 percent wait listed in the first year of renal failure. Asian-Americans are the most likely to be wait listed (37.9 percent in the first year) compared with 30.5 percent among white persons. Wait listing rates by diagnosis mirror those of transplantation, again reflecting in part, age differences among causes of renal failure.

Transplantation rates after wait listing are shown in [Table 5](#t5-hcfr-17-2-89){ref-type="table"}. This table differs from the previous two in that the cohort consists of persons wait listed during the 1988-92 period. It includes some persons whose renal failure occured prior to 1988. It also includes all ages. Persons over 55 years of age were excluded from [Tables 2](#t2-hcfr-17-2-89){ref-type="table"} and [3](#t3-hcfr-17-2-89){ref-type="table"} because most ESRD beneficiaries in the upper age groups tend not to be transplant candidates. However, once they have been wait listed, it would seem to be reasonable to follow their access along with other groups.

Between 1988 and 1992, there were 41,168 Medicare beneficiaries who were wait listed on the OPTN national registry ([Table 5](#t5-hcfr-17-2-89){ref-type="table"}). Almost one-half (46.0 percent) of these persons received a transplant within 1 year of wait listing, increasing to three-fourths (77.6 percent) at 3 years after being added to the list At the end of 5 years, 86 percent of persons who did not die or otherwise leave the wait list had received at least one transplant Age was not much of a factor in transplantation after wait listing. At 5 years, 90 percent of persons under 15 years of age at the time of wait listing had received a transplant The lowest transplant rates were found for persons over 65 years of age (80 percent). Males had slightly higher transplant rates than did females. By diagnostic category, 1-year transplantation rates ranged from a high of 52.2 percent for cystic kidney disease to a low of 39.9 percent of persons whose renal failure was attributed to hypertension.

The highest initial rate of transplantation was experienced by white beneficiaries; over one-half were transplanted within 1 year of wait listing. However, the racial difference narrowed in subsequent years. For example, the black rate was only 68 percent as great as the white rate in the first year of wait listing (34.6 percent and 51.0 percent, respectively). For those persons still not transplanted by the end of the second year, the transplantation rate for black patients was 90 percent as great as that for white patients (31.3 percent and 35.0 percent respectively). In years 4 and 5, the transplantation rates for black persons, Native Americans, and Asian-Americans were all greater than the rate for white persons. As a consequence, at the end of 5 years, all races had cumulative transplant rates in excess of 80 percent.

Trend Effects
=============

As is widely known, the incidence of treated renal failure continues to increase. Between 1988 and 1992, the number of newly treated renal failure patients in the Medicare program under 55 years of age increased at an annual rate of 6.6 percent ([@b8-hcfr-17-2-89]). New entries into the OPTN wait list increased from 10,339 in 1988 to 13,026 in 1993, an annual increase of 5.4 percent ([Table 1](#t1-hcfr-17-2-89){ref-type="table"}).[^7^](#fn7-hcfr-17-2-89){ref-type="fn"} However, the number of transplants has not kept pace with the number of eligible patients. Total transplants for the population under 55 years of age increased by only 2.1 percent per year between 1988 and 1992 ([@b8-hcfr-17-2-89]). In addition, the total transplant number includes retransplants, which obscure the measure of access to initial transplant. These patterns cannot help but have a negative effect on the measures of access to transplantation. Trend effects are explored in the tables which follow.

[Table 6](#t6-hcfr-17-2-89){ref-type="table"} shows the transplant rate within 1 year of renal failure by ESRD incident year. Of the 13,962 persons under 55 years of age whose renal failure occured in 1988, 18.6 percent received a transplant within 1 year of their renal failure date. This transplant rate declined in each of the following years to 13.5 percent in 1992. The decline was evident across all age, sex, and race groups. There were a couple of exceptions within the diagnostic categories. Persons whose renal failure was attributed to either interstitial nephritis or obstructive nephropathy actually had higher rates of transplantation in 1992 than in 1988.

Access to the OPTN wait list did not change noticeably during the 1988-92 time period ([Table 7](#t7-hcfr-17-2-89){ref-type="table"}). The rate of wait listing within 1 year of renal failure was fairly constant across all years, ranging from a low of 25.1 percent in 1990 to a high of 26.7 percent in 1988. All age, gender, race and diagnostic categories had steady rates of wait listing during these years.

Transplantation within 1 year of wait listing has decreased markedly, as shown in [Table 8](#t8-hcfr-17-2-89){ref-type="table"}. In 1988, over one-half (55.4 percent) of persons entering the OPTN wait list received a transplant within 1 year of wait listing. By 1992, the percent of persons transplanted within 1 year had declined to 38.5 percent. Declines in transplant rates were seen across all age, gender, race, and diagnostic categories. The declines were not uniform by race. In 1988, the median waiting time before transplantation (not shown) for white and black persons was 308 days and 439 days, respectively. By 1991,[^8^](#fn8-hcfr-17-2-89){ref-type="fn"} wait times for white persons had increased by 25 percent to 384 days but had increased by 61 percent for black persons to 705 days. During the same period, median wait times increased by 12 percent for Native Americans (483 and 543 days, respectively) and by 27 percent for Asian-Americans (435 and 551 days, respectively).

Multivariate Analyses
=====================

[Table 9](#t9-hcfr-17-2-89){ref-type="table"} shows the results of the proportional hazards models.[^9^](#fn9-hcfr-17-2-89){ref-type="fn"} Race had a significant impact on all three measures of transplant access. Black persons are only 37 percent as likely as white persons to get a transplant (including living donor). They are only 64 percent as likely as white persons to get on the wait list and only 66 percent as likely to get a cadaver transplant after being wait listed. Native Americans also trail white persons in all three access measures, but not to the same degree as black persons. Asian-Americans have lower rates than white persons for all transplantation and wait longer for a cadaver transplant after wait listing. However, they are 32 percent more likely than white persons to register on the wait list. The lower overall tranplantation rate for Asian-Americans is contrary to the results shown in [Table 3](#t3-hcfr-17-2-89){ref-type="table"}. This is probably due to the fact that fewer Asian-Americans are diabetic, thus inflating their unadjusted rate relative to white persons.

Other covariates operated in the expected directions. Age is negatively related to overall transplantation. Age is less strongly related to getting on the wait list and the age effect becomes even less pronounced for transplantation after being wait listed. Males are higher than females on all three measures of access. Causes of renal failure are similar to age in their effects. There are relatively strong effects on the first two measures, but little effect on access after wait listing.

Discussion
==========

This article has attempted to expand our knowledge of access to transplantation by examining a new measure of transplant access and comparing it with two more traditional measures of access. In order to qualify for a cadaver transplant, a person must first enroll on the national OPTN waiting list. Prior to this study, no national-level analysis of this process had been done. The successful matching of the HCFA and OPTN data bases has shown the importance of a measure of this level of access. While it remains true that black ESRD beneficiaries lag behind white ESRD beneficiaries in transplantation after wait list enrollment, a similar disparity exists in the primary step of getting on the wait list in the first place. The importance of the enrollment process is further shown in the case of Asian-Americans. This group has a lower rate of transplantation after wait listing than do white persons. However, the greater enrollment rate on the wait list means that Asian-Americans overtake white persons in cumulative transplantation rate within 5 years after renal failure.

Previous analyses of wait times on the OPTN wait list have emphasized median wait times. While median wait time is an adequate single measure of access, it does not show how relative access can change over time. By tracking patients out as far as 5 years from initial OPTN enrollment, this study has shown that there is a certain amount of equalization in access across racial groups over time. UNOS (the private organization which operates the OPTN under contract to the government) has long recognized the problem of equitable access to transplantation for minority patients. Recently, UNOS has revised the point system for organ allocation to decrease the weight given to donor/recipient human leukocyte antigen (HLA)[^10^](#fn10-hcfr-17-2-89){ref-type="fn"} matching and increased the weight given to time on the wait list. Both of these measures should serve to increase minority access rates ([@b6-hcfr-17-2-89]).

The fact remains, however, that no matter what measure of transplant access is used, black beneficiaries fare worse than either white, Asian-American, or Native American beneficiaries. They are the least likely get on the national wait list, and have longer wait times once they do get wait listed. Consequently, their overall transplant rates lag far behind the other racial groups.[^11^](#fn11-hcfr-17-2-89){ref-type="fn"} In addition, wait times following OPTN enrollment increased more for black patients than for any other racial group between 1988 and 1991.

The analyses presented in this article do not address the reasons behind transplant access problems. Many others have addressed these issues. For example, [@b15-hcfr-17-2-89], [@b10-hcfr-17-2-89], and [@b6-hcfr-17-2-89] have shown that biological factors play a significant role in the ability to match cadaver kidneys with persons on the OPTN. Others have shown that attitudinal factors play a part in the low transplant rates among black persons ([@b1-hcfr-17-2-89]; [@b11-hcfr-17-2-89]; [@b13-hcfr-17-2-89]).

A number of other issues also were not addressed by this study. For example, these analyses were only concerned with initial transplantation. Repeat transplantation following rejection is another access issue. About 13 percent of kidney transplants are repeat transplants ([@b8-hcfr-17-2-89]). Other issues important to our understanding of transplant access include multiple listing (patients registering with more than one transplant center) and economic and sociological factors affecting decisions to enter and continue with the transplant process. Current studies which are addressing some of these issues include a Robert Wood Johnson study of physician attitudes and patient preferences about transplantation and an Agency for Health Care Policy and Research study of multiple listing on the OPTN.

The importance of initially getting on the wait list suggests that measures designed to increase black enrollment on the OPTN (such as education and outreach efforts) should improve access to transplantation for black persons. However, the trend data clearly show the crucial limiting factor of the organ shortage. The incidence of treated renal failure and the enrollment on the OPTN continue to grow at rates greater than the number of available organs. Consequently, post-enrollment transplant wait times have increased. Without significant increases in cadaver donation rates, wait times will continue to increase for all racial groups.

The author is with the Office of Research and Demonstrations, Health Care Financing Administration (HCFA). The opinions expressed are those of the author and do not necessarily reflect those of the Public Health Service or HCFA.

The United Network for Organ Sharing (UNOS) Statement of Principles and Objectives of Equitable Organ Allocation was published in the August 1994 *UNOS Update* ([@b17-hcfr-17-2-89]). It deals with a wide array of thorny and often conflicting issues, including medical utility, cost/benefit, justice, autonomy of the individual, and accountability. The difficulty in conceptualizing, let alone measuring, access is addressed in that publication.

Although the OPTN data base contains information on Hispanic ethnicity, the ESRD PMMIS did not add this item until mid-1995. Because the HCFA population served as the denominator for most of the analyses, it was not possible to break out this population separately.

The HCFA-2745 was used to collect data by HCFA prior to June 1994. At that time, the role of data collection was assumed by OPTN. Since then, all kidney transplant data have been collected by OPTN and routinely forwarded to HCFA.

The access measures were also calculated including all age groups. The results of the racial comparisons remained the same.

Reasons for leaving the wait list other than by receiving a transplant include death (32 percent), medically unsuitable (18 percent), moved (12 percent), refused transplant (5 percent), and all other (33 percent).

The 5-year transplant rate is interpretable for those who survive for 5 years. Due to the high mortality rate among dialysis patients, almost one-half will die within 5 years. Due to favorable selection, about three-fourths of persons will survive for 5 years on dialysis after being wait listed.

The rates of increase for ESRD incidence and OPTN enrollment are not strictly comparable because the OPTN numbers include all age groups and persons whose renal failure occurred in prior years.

Median wait time could not be calculated for black persons in 1992 due to insufficient follow-up time.

As previously noted, the univariate analyses, particularly for post wait listing transplantation, show that the proportionality assumption underlying this hazards model is not met. The coefficients, therefore, represent the average hazard during the entire time span. Relative hazard rates at the beginning and end of the time span are likely to be different, especially for racial groups.

HLA are the major "tissue type" proteins present on cells that are responsible for rejection by one person of the tissues of another person. As such, they present one of the major barriers to organ transplantation.

Black persons have the lowest rate of transplantation from living donors, also contributing to their low overall rate.
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###### Percent of OPTN Registrants Matched to Medicare ESRD Enrollment File, by Year of OPTN Entry

  Year          OPTN Entries   Percent Match With HCFA ESRD PMMIS
  ------------- -------------- ------------------------------------
  Before 1987   4,556          87.8
  1987          7,825          88.2
  1988          10,339         88.3
  1989          10,528         89.4
  1990          10,943         89.6
  1991          11,325         89.8
  1992          12,508         87.9
  1993          13,026         81.3

NOTES: OPTN is Organ Procurement and Transplantation Network. ESRD is end stage renal disease. HCFA is Health Care Financing Administration. ESRD PMMIS is ESRD Program Management and Medical Information System.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System (April 1994 Update); United Network for Organ Sharing: Organ Procurement and Transplantation Network Wait List and Removal Data Sets, May 1994 Update.

###### Demographic Characteristics of Medicare ESRD Incident Population 55 Years of Age or Under: 1988-92

  Characteristic                All Persons   Asian-American   Black    White    Native American   Other/Unknown
  ----------------------------- ------------- ---------------- -------- -------- ----------------- ---------------
  Total                         79,527        1,806            28,541   46,678   1,130             1,372
  **Disease**                   Percent                                                            
  Diabetes                      33.3          23.9             24.5     39.0     59.1              14.4
  Glomerulonephritis            17.5          32.1             16.1     18.1     15.0              12.2
  Hypertension                  18.6          15.9             34.1     9.9      8.7               6.2
  All Other                     30.5          28.1             25.4     33.0     17.3              67.2
  **Sex**                                                                                          
  Male                          58.7          52.8             59.8     58.5     56.9              53.3
  **Age**                                                                                          
  0-14                          2.6           2.9              1.4      3.3      2.3               3.6
  Years 15-24                   7.7           9.8              7.2      7.9      5.3               11.5
  Years 25-34                   20.3          18.5             19.8     20.8     12.3              19.5
  Years 35-44                   30.6          30.7             32.6     29.5     26.6              26.7
  Years 45-54 Years             38.9          38.2             39.0     38.4     53.5              38.7
  Mean Age (Years)              39.9          39.6             40.4     39.5     43.0              38.8
  Rate per Million Population   81            57               224      61       131               ---

NOTES: ESRD is end stage renal disease.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incident Cohort (April 1994 Update).

###### Cumulative Transplantation Rate Following Renal Failure for Medicare ESRD Beneficiaries 55 Years of Age or Under, by Selected Demographic Characteristics

  Characteristic            *n*      Percent Transplanted                
  ------------------------- -------- ---------------------- ------------ ------------
  Total                     79,527   16.1 (0.2)             36.7 (0.3)   46.1 (0.4)
  **Age**                                                                
  Under 15 Years            2,041    45.7 (1.1)             74.0 (1.1)   80.3 (1.2)
  15-24 Years               6,163    30.1 (0.6)             57.4 (0.7)   68.9 (0.8)
  25-34 Years               16,128   22.6 (0.3)             47.5 (0.5)   57.7 (0.6)
  35-44 Years               24,296   15.6 (0.2)             37.1 (0.4)   46.4 (0.5)
  45-54 Years               30,899   8.1 (0.2)              23.6 (0.3)   31.4 (0.4)
  **Sex**                                                                
  Male                      46,699   16.8 (0.2)             38.5 (0.3)   47.8 (0.4)
  Female                    32,828   15.2 (0.2)             34.7 (0.3)   44.2 (0.4)
  **Race**                                                               
  Asian-American            1,806    15.5 (0.9)             43.7 (1.4)   58.2 (1.8)
  Black                     28,541   6.0 (0.1)              20.8 (0.3)   30.3 (0.4)
  White                     46,678   22.7 (0.2)             47.4 (0.3)   56.7 (0.4)
  Native American           1,130    12.1 (1.0)             29.4 (1.6)   38.9 (2.2)
  Other/Unknown             1,372    6.2 (0.7)              15.7 (1.2)   20.2 (1.7)
  **Primary Diagnosis**                                                  
  Diabetes                  26,501   13.3 (0.2)             31.5 (0.4)   39.6 (0.5)
  Glomerulonephritis        13,945   23.2 (0.4)             49.0 (0.5)   59.1 (0.6)
  Hypertension              14,804   8.5 (0.2)              27.0 (0.4)   36.4 (0.6)
  Cystic Kidney Disease     3,196    25.5 (0.8)             53.7 (1.0)   62.7 (1.2)
  Interstitial Nephritis    2,346    22.2 (0.9)             44.1 (1.2)   53.4 (1.5)
  Obstructive Nephropathy   1,199    24.9 (1.3)             44.6 (1.6)   53.8 (2.0)
  Other                     7,138    16.1 (0.5)             37.9 (0.7)   48.9 (1.0)
  Unknown                   4,264    19.1 (0.6)             42.0 (0.9)   50.9 (1.1)
  Missing                   6,134    19.0 (0.5)             35.5 (0.7)   44.1 (0.9)

NOTES: ESRD is end stage renal disease. Standard errors are in parentheses.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update).

###### Cumulative Enrollment of Medicare ESRD Beneficiaries 55 Years of Age and Under on the OPTN National Wait List, by Selected Demographic Characteristics

  Characteristic            *n*      Percent Transplanted                
  ------------------------- -------- ---------------------- ------------ ------------
  Total                     79,527   25.8 (0.2)             41.5 (0.3)   47.2 (0.3)
  **Age**                                                                
  Under 15 Years            2,041    25.7 (1.0)             40.6 (1.2)   46.4 (1.3)
  15-24 Years               6,163    34.4 (0.6)             52.6 (0.7)   59.4 (0.8)
  25-34 Years               16,128   32.5 (0.4)             49.8 (0.4)   55.9 (0.5)
  35-44 Years               24,296   28.2 (0.3)             44.3 (0.4)   49.6 (0.4)
  45-54 Years               30,899   18.6 (0.2)             32.7 (0.3)   37.6 (0.4)
  **Sex**                                                                
  Male                      46,699   26.9 (0.2)             42.8 (0.3)   48.4 (0.3)
  Female                    32,828   24.3 (0.2)             40.0 (0.3)   45.8 (0.4)
  **Race**                                                               
  Asian-American            1,806    37.9 (1.2)             57.4 (1.3)   63.2 (1.6)
  Black                     28,541   17.8 (0.2)             34.0 (0.3)   40.4 (0.4)
  White                     46,678   30.5 (0.2)             46.0 (0.3)   51.1 (0.3)
  Native American           1,130    22.3 (1.3)             35.5 (1.6)   43.4 (2.1)
  Other/Unknown             1,372    19.9 (1.1)             35.3 (1.5)   42.1 (1.9)
  **Primary Diagnosis**                                                  
  Diabetes                  26,501   22.7 (0.3)             36.9 (0.3)   40.9 (0.4)
  Glomerulonephritis        13,945   34.0 (0.4)             51.4 (0.5)   57.4 (0.5)
  Hypertension              14,804   22.1 (0.3)             38.6 (0.4)   45.0 (0.6)
  Cystic Kidney Disease     3,196    42.0 (0.9)             58.0 (0.9)   64.2 (1.1)
  Interstitial Nephritis    2,346    28.3 (0.9)             43.1 (1.1)   49.2 (1.3)
  Obstructive Nephropathy   1,199    20.8 (1.2)             33.9 (1.5)   40.6 (2.0)
  Other                     7,138    21.4 (0.5)             39.6 (0.7)   46.8 (0.9)
  Unknown                   4,264    29.3 (0.7)             45.1 (0.9)   51.1 (1.0)
  Missing                   6,134    23.0 (0.6)             37.1 (0.7)   41.5 (0.8)

NOTES: ESRD is end stage renal disease. OPTN is Organ Procurement and Transplantation Network. Standard errors are in parentheses.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update); United Network for Organ Sharing: Organ Procurement and Transplantation Network Wait List and Removal Data Sets, May 1994 Update.

###### Cumulative Transplantation Rate Following OPTN Wait Listing for Medicare ESRD Beneficiaries, by Selected Demographic Characteristics

  Characteristic            *n*      Percent Transplanted                
  ------------------------- -------- ---------------------- ------------ ------------
  Total                     41,168   46.0 (0.3)             77.6 (0.3)   85.8 (0.3)
  **Age**                                                                
  Under 15 Years            843      58.5 (1.7)             58.5 (1.7)   90.0 (1.7)
  15-24 Years               3,103    48.4 (0.9)             81.9 (0.9)   89.5 (1.0)
  25-34 Years               8,203    48.0 (0.6)             79.2 (0.6)   87.3 (0.7)
  35-44 Years               10,881   46.7 (0.5)             78.5 (0.5)   86.7 (0.6)
  45-54 Years               9,702    43.7 (0.5)             75.4 (0.6)   84.2 (0.7)
  55-64 Years               6,607    43.6 (0.6)             75.5 (0.7)   82.9 (1.0)
  65-74 Years               1,786    43.7 (1.2)             71.3 (1.5)   80.0 (2.8)
  75 Years or Over          43       49.4 (7.9)             79.8 (8.8)   79.8 (8.8)
  **Sex**                                                                
  Male                      25,000   47.4 (0.3)             79.2 (0.3)   87.7 (0.4)
  Female                    16,168   43.8 (0.4)             75.1 (0.4)   83.0 (0.5)
  **Race**                                                               
  Asian-American            1,207    40.4 (1.4)             75.9 (1.5)   86.6 (1.8)
  Black                     10,427   34.6 (0.5)             69.0 (0.6)   81.0 (0.8)
  White                     28,513   51.0 (0.3)             81.6 (0.3)   88.2 (0.4)
  Native American           500      37.4 (2.2)             73.2 (2.7)   84.8 (3.1)
  Other/Unknown             521      22.7 (1.9)             41.4 (2.6)   45.2 (3.4)
  **Primary Diagnosis**                                                  
  Diabetes                  10,862   47.5 (0.5)             77.5 (0.6)   86.1 (0.8)
  Glomerulonephritis        9,210    47.3 (0.5)             79.7 (0.5)   87.9 (0.6)
  Hypertension              7,254    39.9 (0.6)             74.2 (0.7)   83.9 (0.9)
  Cystic Kidney Disease     3,207    52.2 (0.9)             85.2 (0.8)   91.1 (0.9)
  Interstitial Nephritis    1,463    47.0 (1.3)             80.1 (1.3)   89.2 (1.7)
  Obstructive Nephropathy   577      49.5 (2.1)             79.2 (2.1)   89.7 (2.7)
  Other                     2,875    43.9 (1.0)             74.0 (1.1)   82.6 (1.3)
  Unknown                   2,499    49.5 (1.0)             79.4 (1.0)   87.3 (1.2)
  Missing                   3,221    42.5 (0.9)             70.8 (1.0)   77.9 (1.1)

NOTES: OPTN is Organ Procurement and Transplantation Network. ESRD is end stage renal disease. Standard errors are in parentheses.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update); United Network for Organ Sharing: Organ Procurement and Transplantation Network Wait List and Removal Data Sets, May 1994 Update.

###### Transplantation Within 1 Year of Renal Failure for Medicare ESRD Beneficiaries 55 Years of Age or Under, by Selected Demographic Characteristics and Year of Renal Failure

  Characteristic            1988     1989         1990     1991         1992                                                 
  ------------------------- -------- ------------ -------- ------------ -------- ------------ -------- ------------ -------- ------------
  Total                     13,962   18.6 (0.3)   15,116   17.3 (0.3)   15,820   16.0 (0.3)   16,842   15.8 (0.3)   17,787   13.5 (0.3)
  **Age**                                                                                                                    
  Under 15 Years            388      48.9 (2.6)   392      48.2 (2.6)   433      41.8 (2.4)   440      48.7 (2.4)   388      40.7 (2.5)
  15-24 Years               1,215    33.9 (1.4)   1,251    32.1 (1.3)   1,210    29.5 (1.3)   1,210    29.1 (1.3)   1,277    25.9 (1.2)
  25-34 Years               2,954    24.1 (0.8)   3,228    23.3 (0.8)   3,263    23.0 (0.8)   3,334    23.3 (0.7)   3,349    19.7 (0.7)
  35-44 Years               4,151    18.0 (0.6)   4,479    16.8 (0.6)   4,879    15.6 (0.5)   5,252    15.2 (0.5)   5,535    13.0 (0.5)
  45-54 Years               5,254    9.8 (0.4)    5,766    8.8 (0.4)    6,035    7.5 (0.3)    6,606    7.7 (0.3)    7,238    7.1 (0.3)
  **Sex**                                                                                                                    
  Male                      8,150    19.8 (0.5)   8,884    18.1 (0.4)   9,376    16.9 (0.4)   9,917    16.1 (0.4)   10,372   13.7 (0.3)
  Female                    5,812    16.8 (0.5)   6,232    16.3 (0.5)   6,444    14.6 (0.4)   6,925    15.5 (0.4)   7,415    13.2 (0.4)
  **Race**                                                                                                                   
  Asian-American            295      19.7 (2.3)   316      19.0 (2.2)   378      11.1 (1.6)   373      15.7 (1.9)   444      13.5 (1.6)
  Black                     4,783    7.5 (0.4)    5,460    6.5 (0.3)    5,544    5.8 (0.3)    6,137    5.5 (0.3)    6,617    5.2 (0.3)
  White                     8,426    25.2 (0.5)   8,907    24.3 (0.5)   9,382    22.5 (0.4)   9,799    22.7 (0.4)   10,164   19.2 (0.4)
  Native American           201      10.8 (2.2)   206      13.9 (2.4)   216      11.7 (2.2)   240      13.8 (2.3)   267      10.5 (1.9)
  Other/Unknown             257      8.8 (1.8)    227      5.2 (1.5)    300      6.8 (1.5)    293      5.1 (1.3)    295      5.3 (1.3)
  **Primary Diagnosis**                                                                                                      
  Diabetes                  4,241    16.5 (0.6)   5,035    14.7 (0.5)   5,278    13.0 (0.5)   5,821    13.1 (0.5)   6,126    10.5 (0.4)
  Glomerulonephritis        2,616    25.2 (0.9)   2,799    25.6 (0.8)   2,803    22.7 (0.8)   2,835    22.6 (0.8)   2,892    19.9 (0.8)
  Hypertension              2,423    9.8 (0.6)    2,722    8.7 (0.6)    2,884    8.8 (0.5)    3,185    8.2 (0.5)    3,590    7.4 (0.4)
  Cystic Kidney Disease     616      28.8 (1.8)   607      24.7 (1.8)   608      25.2 (1.8)   682      26.4 (1.7)   683      22.5 (1.6)
  Interstitial Nephritis    429      20.4 (2.0)   418      23.5 (2.1)   492      19.9 (1.8)   537      24.3 (1.9)   470      22.8 (2.0)
  Obstructive Nephropathy   207      22.8 (3.0)   213      23.5 (3.0)   215      24.2 (3.0)   271      26.9 (2.8)   293      26.1 (2.6)
  Other                     1,150    17.6 (1.2)   1,343    18.2 (1.1)   1,400    16.6 (1.0)   1,587    15.6 (1.0)   1,658    13.3 (0.9)
  Unknown                   847      17.8 (1.4)   800      18.5 (1.4)   812      20.1 (1.4)   900      19.3 (1.3)   905      19.4 (1.3)
  Missing                   1,433    22.5 (1.1)   1,179    19.1 (1.2)   1,328    18.5 (1.1)   1,024    18.9 (1.3)   1,170    15.4 (1.1)

NOTES: ESRD is end stage renal disease. Standard errors are in parentheses.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update).

###### Enrollment on OPTN Wait List Within 1 Year of Renal Failure for Medicare ESRD Beneficiaries 55 Years of Age or Under, by Selected Demographic Characteristics and Year of Renal Failure

  Characteristic            1988     1989         1990     1991         1992                                                 
  ------------------------- -------- ------------ -------- ------------ -------- ------------ -------- ------------ -------- -------------
  Total                     13,962   26.7 (0.4)   15,116   26.2 (0.4)   15,820   25.1 (0.4)   16,842   25.6 (0.3)   17,787   25.6 (0.3)
  **Age**                                                                                                                    
  Under 15 Years            388      25.9 (2.3)   392      28.5 (2.3)   433      25.5 (2.1)   440      24.5 (2.1)   388      24.3 (2.2)
  15-24 Years               1,215    35.7 (1.4)   1,251    33.9 (1.4)   1,210    32.6 (1.4)   1,210    34.8 (1.4)   1,277    35.2 (1.4)
  25-34 Years               2,954    32.1 (0.9)   3,228    33.0 (0.8)   3,263    31.6 (0.8)   3,334    32.5 (0.8)   3,349    33.1 (0.8)
  35-44 Years               4,151    30.3 (0.7)   4,479    29.1 (0.7)   4,879    27.1 (0.7)   5,252    28.0 (0.6)   5,535    27.2 (0.6)
  45-54 Years               5,254    18.6 (0.6)   5,766    18.2 (0.5)   6,035    18.3 (0.5)   6,606    18.5 (0.5)   7,238    19.1 (0.5)
  **Sex**                                                                                                                    
  Male                      8,150    27.1 (0.5)   8,884    27.7 (0.5)   9,376    26.8 (0.5)   9,917    26.5 (0.5)   10,372   26.5 (0.4)
  Female                    5,812    26.2 (0.6)   6,232    24.2 (0.6)   6,444    22.7 (0.5)   6,925    24.4 (0.5)   7,415    24.3 (0.5)
  **Race**                                                                                                                   
  Asian-American            295      38.8 (2.9)   316      40.3 (2.8)   378      37.8 (2.5)   373      39.1 (2.6)   444      34.5 (2.3)
  Black                     4,783    19.1 (0.6)   5,460    16.8 (0.5)   5,544    17.5 (0.5)   6,137    17.6 (0.5)   6,617    18.2 (0.5)
  White                     8,426    30.8 (0.5)   8,907    31.8 (0.5)   9,382    29.4 (0.5)   9,799    30.4 (0.5)   10,164   30.2 (0.5)
  Native American           201      26.7 (3.2)   206      24.4 (3.0)   216      19.0 (2.7)   240      21.6 (2.7)   267      20.6 (2.5)
  Other/Unknown             257      20.6 (2.6)   227      15.1 (2.5)   300      19.9 (2.4)   293      19.2 (2.4)   295      23.7 (2.5)
  **Primary Diagnosis**                                                                                                      
  Diabetes                  4,241    24.9 (0.7)   5,035    23.7 (0.6)   5,278    20.9 (0.6)   5,821    22.1 (0.6)   6,126    22.5 (0.5)
  Glomerulonephritis        2,616    34.2 (0.9)   2,799    34.7 (0.9)   2,803    32.6 (0.9)   2,835    34.0 (0.9)   2,892    34.6 (0.9)
  Hypertension              2,423    21.6 (0.9)   2,722    21.5 (0.8)   2,884    23.1 (0.8)   3,185    21.9 (0.7)   3,590    22.3 (0.7).
  Cystic Kidney Disease     616      40.1 (2.0)   607      39.5 (2.0)   608      41.4 (2.0)   682      47.2 (1.9)   683      41.5 (1.9)
  Interstitial Nephritis    429      25.5 (2.1)   418      27.6 (2.2)   492      29.1 (2.1)   537      29.8 (2.0)   470      29.0 (2.1)
  Obstructive Nephropathy   207      26.5 (3.2)   213      17.7 (2.7)   215      19.5 (2.8)   271      19.6 (2.5)   293      21.3 (2.4)
  Other                     1,150    23.0 (1.3)   1,343    22.2 (1.2)   1,400    21.8 (1.2)   1,587    19.6 (1.1)   1,658    20.9 (1.1)
  Unknown                   847      27.4 (1.6)   800      26.6 (1.6)   812      29.5 (1.6)   900      32.8 (1.6)   905      29.9 (1.6)
  Missing                   1,433    23.9 (1.2)   1,179    25.6 (1.3)   1,328    22.4 (1.2)   1,024    20.4 (1.3)   1,170    22.0 (1.2)

NOTES: OPTN is Organ Procurement and Transplantation Network. ESRD is end stage renal disease. Standard errors are in parentheses.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update); United Network for Organ Sharing: Organ Procurement and Transplantation Network Wait List and Removal Data Sets, May 1994 Update.

###### Transplantation Within 1 Year of Enrollment in OPTN for Medicare ESRD Beneficiaries, by Selected Demographic Characteristics and Year of Wait Listing

  Characteristic            1988    1989          1990    1991          1992                                                
  ------------------------- ------- ------------- ------- ------------- ------- ------------- ------- ------------- ------- -------------
  Total                     6,710   55.4 (0.6)    7,621   49.6 (0.6)    8,242   46.4 (0.6)    8,830   43.5 (0.5)    9,765   38.5 (0.5)
  **Age**                                                                                                                   
  Under 15 Years            170     66.5 (3.7)    163     59.7 (3.9)    157     56.7 (4.1)    192     56.9 (3.7)    161     52.2 (4.1)
  15-24 Years               583     58.2 (2.1)    654     53.5 (2.0)    620     48.4 (2.1)    605     44.8 (2.1)    641     37.3 (2.0)
  25-34 Years               1,407   57.2 (1.4)    1,621   50.2 (1.3)    1,682   46.9 (1.3)    1,679   44.7 (1.3)    1,814   42.7 (1.2)
  35-44 Years               1,860   55.0 (1.2)    2,006   51.5 (1.1)    2,177   48.0 (1.1)    2,354   44.5 (1.1)    2,484   37.4 (1.0)
  45-54 Years               1,508   53.7 (1.3)    1,762   46.7 (1.2)    1,908   44.0 (1.2)    2,102   40.3 (1.1)    2,422   38.0 (1.0)
  55-64 Years               966     52.0 (1.7)    1,137   47.4 (1.5)    1,337   45.4 (1.4)    1,492   42.0 (1.3)    1,675   36.1 (1.2)
  65-74 Years               213     55.5 (3.5)    273     44.3 (3.1)    355     42.3 (2.7)    395     46.2 (2.6)    550     37.7 (2.2)
  75 Years or Over          3       100.0 (0.0)   5       40.0 (21.9)   6       83.3 (15.2)   11      54.6 (15.0)   18      25.8 (11.1)
  **Sex**                                                                                                                   
  Male                      4,118   57.6 (0.8)    4,605   50.7 (0.8)    5,065   48.6 (0.7)    5,310   44.2 (0.7)    5,902   39.4 (0.7)
  Female                    2,592   51.8 (1.0)    3,016   48.0 (0.9)    3,177   42.9 (0.9)    3,520   42.4 (0.9)    3,863   37.2 (0.8)
  **Race**                                                                                                                  
  Asian-American            188     46.8 (3.8)    215     41.6 (3.4)    275     41.1 (3.0)    236     37.3 (3.2)    293     37.4 (2.9)
  Black                     1,550   45.9 (1.3)    1,898   39.6 (1.2)    2,025   35.8 (1.1)    2,319   31.4 (1.0)    2,635   26.2 (0.9)
  White                     4,818   59.2 (0.7)    5,326   54.1 (0.7)    5,732   51.1 (0.7)    6,063   48.9 (0.7)    6,574   44.2 (0.6)
  Native American           78      43.8 (5.8)    100     41.5 (5.0)    101     34.0 (4.9)    98      39.8 (5.1)    123     30.7 (4.3)
  Other/Unknown             76      37.8 (5.7)    82      24.8 (4.9)    109     23.1 (4.1)    114     17.8 (3.7)    140     17.1 (3.3)
  **Primary Diagnosis**                                                                                                     
  Diabetes                  1,623   55.4 (1.3)    1,993   51.1 (1.2)    2,129   47.3 (1.1)    2,362   46.0 (1.1)    2,755   41.5 (1.0)
  Glomerulonephritis        1,581   56.4 (1.3)    1,773   51.1 (1.2)    1,883   48.3 (1.2)    1,901   44.6 (1.2)    2,072   38.6 (1.1)
  Hypertension              1,099   51.1 (1.5)    1,220   44.1 (1.5)    1,477   41.4 (1.3)    1,619   37.1 (1.2)    1,839   31.9 (1.1)
  Cystic Kidney Disease     504     62.7 (2.2)    642     51.5 (2.0)    615     54.8 (2.0)    699     47.8 (1.9)    747     47.4 (1.9)
  Interstitial Nephritis    265     54.9 (3.1)    264     50.7 (3.2)    280     46.0 (3.1)    333     43.0 (2.8)    321     42.6 (2.8)
  Obstructive Nephropathy   95      55.3 (5.2)    107     53.3 (4.9)    113     45.8 (4.8)    119     45.5 (4.8)    143     48.7 (4.4)
  Other                     455     52.8 (2.4)    503     51.2 (2.3)    581     43.9 (2.1)    637     41.2 (2.0)    699     35.4 (1.9)
  Unknown                   450     60.3 (2.4)    436     52.9 (2.4)    480     50.4 (2.3)    544     47.9 (2.2)    589     39.3 (2.1)
  Missing                   638     52.7 (2.0)    683     45.2 (2.0)    684     41.2 (1.9)    616     40.4 (2.0)    600     32.2 (2.0)

NOTES: OPTN is Organ Procurement and Transplantation Network. ESRD is end stage renal disease. Standard errors are in parentheses.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update); United Network for Organ Sharing: Organ Procurement and Transplantation Network Wait List Data Set, May 1994 Update.

###### Relative Likelihood of Transplantation, Wait Listing, and Post Wait Listing Transplant, by Selected Demographic Characteristics: Results of Proportional Hazards Modeling

  Covariate                 Comparison           Relative Risk Ratios                                                                                           
  ------------------------- -------------------- ----------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Black                     White                [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.374   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.642      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.655
  Asian-American            White                [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.826   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.321      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.800
  Native American           White                [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.668   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.828      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.710
  Under 15 Years            25-34 Years          [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.911   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.703      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.293
  15-24 Years               25-34 Years          [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.291   [^ns^](#tfn17-hcfr-17-2-89){ref-type="table-fn"} 1.033   [\*\*](#tfn18-hcfr-17-2-89){ref-type="table-fn"}1.074
  35-44 Years               25-34 Years          [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.705   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.839      [\*\*](#tfn18-hcfr-17-2-89){ref-type="table-fn"}0.953
  45-54 Years               25-34 Years          [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.400   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.559      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.865
  55-64 Years               25-34 Years          NR                                                    NR                                                       [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.850
  65-74 Years               25-34 Years          NR                                                    NR                                                       [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.773
  75 Years or More          25-34 Years          NR                                                    NR                                                       [^ns^](#tfn17-hcfr-17-2-89){ref-type="table-fn"} 0.931
  Male                      Female               [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.133   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.080      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.136
  Diabetes                  Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.690   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.701      [^ns^](#tfn17-hcfr-17-2-89){ref-type="table-fn"} 0.963
  Hypertension              Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.754   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.843      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.852
  Interstitial Nephritis    Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.841   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.776      [^ns^](#tfn19-hcfr-17-2-89){ref-type="table-fn"} 0.967
  Obstructive Nephropathy   Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.745   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.556      [^ns^](#tfn19-hcfr-17-2-89){ref-type="table-fn"} 0.933
  Cystic Kidney Disease     Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.294   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.394      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}1.157
  Other                     Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.661   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.688      [^ns^](#tfn19-hcfr-17-2-89){ref-type="table-fn"} 0.975
  Unknown                   Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.854   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.869      [^ns^](#tfn19-hcfr-17-2-89){ref-type="table-fn"} 1.027
  Missing                   Glomerulonephritis   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.707   [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.669      [\*](#tfn17-hcfr-17-2-89){ref-type="table-fn"}0.798

*p* \> 0.001

*p* \> 0.01

*p* \< 0.05

NOTES: NR is not in model.

SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: End Stage Renal Disease Program Management and Medical Information System, 1988-92 Incidence Cohort (April 1994 Update); United Network for Organ Sharing: Organ Procurement and Transplantation Network Wait List and Removal Data Sets, May 1994 Update.
